Tempus Ai Cl A (TEM) Stock Price, Quote & News

Company Profile

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also...

Industry: Health Information Services

Sector: Healthcare

Phone: 800 976 5448

Fax: 800 893 0276

Website: www.tempus.com

Address:

600 West Chicago Avenue, Suite 510, Chicago, United States

OnlyFibs Sep. 7 at 9:10 PM

$TEM Swing Playbook: Weekly Wedge Breakout & Shelf Hold 📈⚡️ $TEM (Tempus AI) is confirming a multi-month falling wedge breakout on the 1W chart, converting previous resistance near $62.11 into structural support. Strong volume accumulation continues to enter as price coils right below $66.50. A firm weekly close above $66.50 opens up a high-velocity squeeze toward major liquidity overhead. BULL PLAN 🐂 • Base Entry Zone: $62.11–$64.76 • Momentum Trigger: $66.50 • Primary Targets: $68.00 ➔ $80.00 • Invalidation Stop: $60.00 BEAR RISK 🐻 • Downside Break: Below $48.50 • Lower Targets: $41.00 ➔ $35.00 #TEM #optionsflow #swingtrading #technicalanalysis #hovdidtechnicalanalysis #hovdid

0 · Reply

pc93 Sep. 6 at 9:18 PM

$TEM continues to trade like a turd. Many many better names right now. This will shake out traders and reward only investors.

0 · Reply

BioTechHealthX Sep. 6 at 6:25 PM

$CERT $GEHC $RDNT $TEM $BFLY Looking for the best AI medicine stocks? These 5 companies are applying artificial intelligence to some of healthcare’s most valuable markets. https://biotechhealthx.com/biotech-news/5-best-cheap-ai-medicine-stocks-to-buy-now/

0 · Reply

Tradeur_Cueilleur Sep. 5 at 5:50 PM

$TEM you're going to hear from these guys soon...

0 · Reply

Loudermilk64 Sep. 5 at 11:47 AM

$TEM yeah. now it looks like they’re gonna dip it to 50 again before going higher unless they drop some good news.

1 · Reply

ieatlightbulbs Sep. 4 at 4:19 PM

$TEM odds are high this pays. Intraday looks like shit psychologically you don’t want it here you want it after it ramps to 70 chasing it.

0 · Reply

JensenNVDA Sep. 4 at 3:51 PM

$TEM this may revisit the $50 range. Long term destined for $100

0 · Reply

ieatlightbulbs Sep. 4 at 3:46 PM

$TEM looks good here vs 63 for 71+ again. Failed pennant into bullflag undercutting sets of highs to run stops. Below back above move with strong demand at 63. Underlining momentum from the initial move from 40 to 70. Good risk levels create demand. Risking 1.5 pints here for over 6. Probably ramps tomorrow or the day after if not today.

1 · Reply

ivanhoff Sep. 4 at 3:28 PM

$TEM is working on its bull flag above its rising 20EMA

0 · Reply

Loudermilk64 Sep. 4 at 2:50 PM

$TEM Might get another dip for the 60? I got a little greedy trying for 2 or 3/pennies better on the BTD.

1 · Reply

Tempus AI initiated with a Neutral at Rothschild & Co Redburn

Sep 4, 2026, 8:30 AM EDT - 3 days ago

Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Sep 2, 2026, 12:04 PM EDT - 5 days ago

Why Moderna's Cancer Vaccine Matters to Investors

DHR HTEC ILMN MRK MRNA NTRA ROG

2026-09-02T11:55:09.000Z - 6 days ago

Cantor Fitzgerald bullish on Tempus AI, initiates with an Overweight

2026-09-02T10:10:13.000Z - 6 days ago

Tempus AI initiated with an Overweight at Cantor Fitzgerald

2026-09-01T09:20:29.000Z - 7 days ago

Tempus AI upgraded to Overweight from Neutral at Piper Sandler

PSNL

Aug 26, 2026, 4:33 PM EDT - 12 days ago

Top Performing Leveraged/Inverse ETFs: 08/23/2026

BITX CONL ETHT ETHU ETU MSTP MSTU

2026-08-24T12:40:41.000Z - 14 days ago

Tempus AI receives FDA clearance for Tempus ECG-PH

Aug 24, 2026, 8:30 AM EDT - 14 days ago

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

2026-08-20T16:05:23.000Z - 18 days ago

Tempus AI rises 10.2%

2026-08-20T14:05:58.000Z - 18 days ago

Tempus AI rises 9.5%

2026-08-20T12:00:29.000Z - 19 days ago

Tempus AI price target raised to $80 from $70 at BTIG

MRK MRNA

Aug 19, 2026, 3:47 PM EDT - 19 days ago

Tempus AI stock is soaring and it has Moderna to thank

2026-08-19T18:15:06.000Z - 19 days ago

‘Prepare for What’s Coming,’ Says Investor About Tempus AI Stock

2026-08-19T17:04:55.000Z - 19 days ago

Tempus AI Stock (TEM) Is Surging 24% on Wednesday – Here’s Why

GILD MRK MRNA PSNL

2026-08-19T16:05:31.000Z - 19 days ago

Tempus AI rises 20.1%

Aug 6, 2026, 9:15 AM EDT - 4 weeks ago

CellCarta Adds Tempus to CDx Commercialization Lab Network

Aug 4, 2026, 8:30 AM EDT - 4 weeks ago

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

Jul 30, 2026, 4:30 PM EDT - 5 weeks ago

Tempus AI Earnings Call Transcript: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 5 weeks ago

Tempus AI Earnings release: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 5 weeks ago

Tempus AI Quarterly report: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 5 weeks ago

Tempus AI Slides: Q2 2026

Jul 30, 2026, 4:01 PM EDT - 5 weeks ago

Tempus Reports Second Quarter 2026 Results

Jul 22, 2026, 8:30 AM EDT - 6 weeks ago

Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine

Jul 20, 2026, 10:44 AM EDT - 7 weeks ago

Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink

PSNL

Jul 20, 2026, 9:00 AM EDT - 7 weeks ago

Tempus AI Transcript: M&A announcement

Jul 20, 2026, 9:00 AM EDT - 7 weeks ago

Tempus AI Press release: M&A announcement

Jul 20, 2026, 9:00 AM EDT - 7 weeks ago

Tempus AI Slides: M&A announcement

Jul 20, 2026, 8:44 AM EDT - 7 weeks ago

Tempus to acquire Personalis for $1.5 billion

PSNL

Jul 20, 2026, 8:30 AM EDT - 7 weeks ago

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

PSNL

Jul 16, 2026, 8:30 AM EDT - 7 weeks ago

Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service

Jul 9, 2026, 9:00 AM EDT - 2 months ago

Tempus to Report Second Quarter 2026 Financial Results on July 30

Jun 25, 2026, 8:30 AM EDT - 2 months ago

Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers

Jun 16, 2026, 5:07 PM EDT - 2 months ago

Tempus AI (TEM) Price Forecast: Consolidation Bottom Breakout Looms

Jun 11, 2026, 8:30 AM EDT - 2 months ago

Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

Jun 9, 2026, 6:00 AM EDT - 3 months ago

Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing

Jun 8, 2026, 2:00 PM EDT - 3 months ago

Tempus AI Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 5, 2026, 4:01 PM EDT - 3 months ago

Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 3, 2026, 8:30 AM EDT - 3 months ago

Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members

Jun 1, 2026, 8:30 AM EDT - 3 months ago

Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH

May 31, 2026, 8:30 AM EDT - 3 months ago

Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development

May 30, 2026, 8:30 AM EDT - 3 months ago

Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community

May 30, 2026, 8:00 AM EDT - 3 months ago

Tempus Introduces ‘Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results

May 29, 2026, 9:15 AM EDT - 3 months ago

Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology

May 29, 2026, 9:00 AM EDT - 3 months ago

Tempus AI Transcript: Investor Day 2026

May 29, 2026, 9:00 AM EDT - 3 months ago

Tempus AI Slides: FY 2026

May 29, 2026, 8:15 AM EDT - 3 months ago

Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio

May 28, 2026, 8:30 AM EDT - 3 months ago

Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology

May 27, 2026, 8:33 AM EDT - 3 months ago

Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows

May 26, 2026, 8:30 AM EDT - 3 months ago

Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 21, 2026, 8:30 AM EDT - 3 months ago

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

May 14, 2026, 8:30 AM EDT - 3 months ago

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

BMY

May 11, 2026, 6:00 AM EDT - 4 months ago

Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

May 8, 2026, 12:59 AM EDT - 4 months ago

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

May 7, 2026, 7:11 AM EDT - 4 months ago

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

May 6, 2026, 8:00 AM EDT - 4 months ago

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

QTRX

May 5, 2026, 4:30 PM EDT - 4 months ago

Tempus AI Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 4 months ago

Tempus AI Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 4 months ago

Tempus AI Slides: Q1 2026

May 5, 2026, 4:30 PM EDT - 4 months ago

Tempus AI Quarterly report: Q1 2026

May 5, 2026, 4:01 PM EDT - 4 months ago

Tempus Reports First Quarter 2026 Results

Apr 29, 2026, 8:30 AM EDT - 4 months ago

Tempus to Host Inaugural Investor Day on May 29, 2026

Apr 28, 2026, 8:30 AM EDT - 4 months ago

Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026

Apr 23, 2026, 8:30 AM EDT - 4 months ago

Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine

Apr 21, 2026, 8:30 AM EDT - 4 months ago

Tempus to Report First Quarter 2026 Financial Results on May 5

Apr 15, 2026, 8:30 AM EDT - 4 months ago

Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring

Apr 14, 2026, 11:45 AM EDT - 4 months ago

Tempus AI Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 8:30 AM EDT - 4 months ago

Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026

Apr 13, 2026, 8:30 AM EDT - 4 months ago

Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care

Apr 9, 2026, 8:30 AM EDT - 5 months ago

Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

GILD

Apr 8, 2026, 4:01 PM EDT - 5 months ago

Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 8:00 AM EDT - 5 months ago

Tempus AI Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 5 months ago

Tempus AI Proxy statement: Proxy filing

Apr 1, 2026, 8:30 AM EDT - 5 months ago

Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease

Mar 17, 2026, 8:30 AM EDT - 5 months ago

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

Mar 11, 2026, 8:30 AM EDT - 6 months ago

Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings

OnlyFibs Sep. 7 at 9:10 PM

0 · Reply

pc93 Sep. 6 at 9:18 PM

$TEM continues to trade like a turd. Many many better names right now. This will shake out traders and reward only investors.

0 · Reply

BioTechHealthX Sep. 6 at 6:25 PM

0 · Reply

Tradeur_Cueilleur Sep. 5 at 5:50 PM

$TEM you're going to hear from these guys soon...

0 · Reply

Loudermilk64 Sep. 5 at 11:47 AM

$TEM yeah. now it looks like they’re gonna dip it to 50 again before going higher unless they drop some good news.

1 · Reply

ieatlightbulbs Sep. 4 at 4:19 PM

$TEM odds are high this pays. Intraday looks like shit psychologically you don’t want it here you want it after it ramps to 70 chasing it.

0 · Reply

JensenNVDA Sep. 4 at 3:51 PM

$TEM this may revisit the $50 range. Long term destined for $100

0 · Reply

ieatlightbulbs Sep. 4 at 3:46 PM

1 · Reply

ivanhoff Sep. 4 at 3:28 PM

$TEM is working on its bull flag above its rising 20EMA

0 · Reply

Loudermilk64 Sep. 4 at 2:50 PM

$TEM Might get another dip for the 60? I got a little greedy trying for 2 or 3/pennies better on the BTD.

1 · Reply

OpenOutcrier Sep. 4 at 12:32 PM

$TEM (+1.1% pre) Tempus AI could capture a lucrative slice of $MRNA Moderna and $MRK Merck’s personalized cancer therapy business, with Personalis at the center of the bet - WSJ https://ooc.bz/l/113324

1 · Reply

NEXTWEEKSBREAKOUTS Sep. 3 at 10:38 PM

$TEM this one burnt me yesterday. I thought I'd try it again today. And it started to do the same thing again I when it went negative. I bailed. Did something else looked at it and said phewy. Should have had a little conviction. I believe this is going to be a rockstar in the next few months. I would have held like a champion if I had just bought the stock instead of buying calls. Try deepvue free. https://app.deepvue.com/register?ref=15HPmEsH

0 · Reply

gogo1927 Sep. 3 at 9:04 PM

$TEM I’m very patient and very bullish see this at $80+ soon 🔜

0 · Reply

PatSoonDiggler Sep. 3 at 7:36 PM

$TEM To those who follow TEM closely; where do you see us on a year? Predict a share price for me. Thanks.

7 · Reply

Swift_Trades Sep. 3 at 6:24 PM

$TEM 📲🔥

0 · Reply

Jblack500 Sep. 3 at 4:57 PM

$TEM $VRTX $HALO $MRK $ARWR ELAN BMY GILD. Current bio basket. New position in TEM at 63.

0 · Reply

AyoRee Sep. 3 at 3:31 PM

$TEM pump coming 🚀

0 · Reply

shortking Sep. 3 at 2:59 PM

$TEM Watch out for that Alzheimer’s study coming out soon… $250

3 · Reply

USMC223556 Sep. 3 at 2:15 PM

$TEM Before the Invasion of the value snatchers penny playing dimwits the 52 week high was $104.32 for months we hung around $90 straight up if your a narrow minded penny playing short go play in another swamp . TEMPUS AI GUIDANCE: $1.605 BILLION PROJECTIONS AND ESTIMATES: AS HIGH AS $1.8–$1.9 BILLION IN 2026 revenue

0 · Reply

BeachTrader777 Sep. 3 at 1:39 PM

$TEM some funky spread shit going on here

0 · Reply

okmfer69 Sep. 3 at 1:00 PM

$TEM everyone saying theyre out with a small profit, or out at break even, are the very definition of "resistance ". Its fine, but when you get frustrated with price action, you and others like you with that mentality are causing it. No one wanted Micron a year ago either, getting out at break even at 110! Hahaha

0 · Reply

Loudermilk64 Sep. 3 at 11:38 AM

$TEM cathy wood done shorting this?

0 · Reply

Market Cap	11.66B
Revenue (ttm)	1.27B
Net Income (ttm)	-245.03M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-19.27%
Debt to Equity Ratio	0.00

Volume	4,574,900
Avg Vol	6,339,548
Day's Range	N/A - N/A
Shares Out	180.44M
Stochastic %K	39%
Beta	3.72
Analysts	Sell
Price Target	$67.13